8-K filed Aug 6, 2026 at 07:33 ET
Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, and revenue of $199.9M (+6% YoY). However, the company lowered full-year 2026 product revenue guidance to $825-855M (from $865-895M) and adjusted EBITDA to $445-470M (from $475-500M), citing weaker-than-expected authorized generic Nucynta pricing. The GAAP net loss of ($15.1M) reflects acquisition-related costs from the recently closed AZSTARYS deal. The ADHD portfolio (JORNAY PM +41% YoY, AZSTARYS $12.9M partial quarter) is strong, but the pain portfolio declined 9% YoY, creating a mixed outlook.